Occupational Asthma Reference

Cannon J, Fitzgerald B, Seed M, Agius R, Jiwany A, Cullinan P, Occupational asthma from tafenoquine in the pharmaceutical industry: implications for QSAR, Occup Med, 2015;65:256-258,https://doi.org/10.1093/occmed/kqu193

Keywords: uk, nc, tafenoquine, QSAR, oa, or, pharmacist,SIC, dual reaction, cr

Known Authors

Paul Cullinan, Royal Brompton Hospital, London, UK Paul Cullinan

Raymond Agius, Centre for Occupational and Environmental Health, Manchester University Raymond Agius

Martin Seed, Manchester University Martin Seed

Julie Cannon, Royal Brompton Hospital London Julie Cannon

If you would like to become a known author and have your picture displayed along with your papers then please get in touch from the contact page. Known authors can choose to receive emails when their papers receive comments.


We report occupational asthma and rhinitis in a formulation pharmacist, employed in the development of tafenoquine. Tafenoquine is a new anti-malarial drug in development; the pure drug substance has an asthma hazard index of zero and previously was not known to be a respiratory sensitizing agent. The implications of this finding for the refinement of quantitative structural analysis of asthmagenic chemicals are discussed.

Full Text


Please sign in or register to add your thoughts.

Oasys and occupational asthma smoke logo